JP2003508527A5 - - Google Patents

Info

Publication number

JP2003508527A5

JP2003508527A5 JP2001522211A JP2001522211A JP2003508527A5 JP 2003508527 A5 JP2003508527 A5 JP 2003508527A5 JP 2001522211 A JP2001522211 A JP 2001522211A JP 2001522211 A JP2001522211 A JP 2001522211A JP 2003508527 A5 JP2003508527 A5 JP 2003508527A5

Authority

JP

Japan

Prior art keywords

group

ring atoms

ring

unsubstituted

nhcoch

Prior art date

2000-08-28

Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)

Withdrawn

Links

• Espacenet
• Global Dossier
• Discuss

• 125000006413 ring segment Chemical group 0.000 description 32
• 150000001875 compounds Chemical class 0.000 description 28
• 125000001424 substituent group Chemical group 0.000 description 22
• 125000000217 alkyl group Chemical group 0.000 description 18
• 125000000623 heterocyclic group Chemical group 0.000 description 17
• 125000002837 carbocyclic group Chemical group 0.000 description 15
• 229920006395 saturated elastomer Polymers 0.000 description 13
• 125000005842 heteroatom Chemical group 0.000 description 10
• 125000001183 hydrocarbyl group Chemical group 0.000 description 9
• 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 9
• 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 8
• 125000003118 aryl group Chemical group 0.000 description 7
• -1 2-hydroxyphenyl Chemical group 0.000 description 6
• 239000003814 drug Substances 0.000 description 6
• 238000004519 manufacturing process Methods 0.000 description 5
• 229940034982 antineoplastic agent Drugs 0.000 description 4
• 239000002246 antineoplastic agent Substances 0.000 description 4
• 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 description 3
• 125000000339 4-pyridyl group Chemical group N1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 description 3
• ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 description 3
• 229930012538 Paclitaxel Natural products 0.000 description 3
• 125000005336 allyloxy group Chemical group 0.000 description 3
• 230000001028 anti-proliverative effect Effects 0.000 description 3
• 229960003668 docetaxel Drugs 0.000 description 3
• 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 3
• 229960001592 paclitaxel Drugs 0.000 description 3
• 239000008194 pharmaceutical composition Substances 0.000 description 3
• RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 3
• 206010028980 Neoplasm Diseases 0.000 description 2
• 208000035269 cancer or benign tumor Diseases 0.000 description 2
• 125000004432 carbon atom Chemical group C* 0.000 description 2
• 229910052757 nitrogen Inorganic materials 0.000 description 2
• 150000003839 salts Chemical class 0.000 description 2
• 239000012453 solvate Substances 0.000 description 2
• UNDYVEDXFDFDRI-UHFFFAOYSA-N 1-(3,4,5-trimethoxyphenyl)prop-2-en-1-one Chemical compound COC1=CC(C(=O)C=C)=CC(OC)=C1OC UNDYVEDXFDFDRI-UHFFFAOYSA-N 0.000 description 1
• 125000004182 2-chlorophenyl group Chemical group [H]C1=C([H])C(Cl)=C(*)C([H])=C1[H] 0.000 description 1
• 125000002941 2-furyl group Chemical group O1C([*])=C([H])C([H])=C1[H] 0.000 description 1
• 125000003762 3,4-dimethoxyphenyl group Chemical group [H]C1=C([H])C(OC([H])([H])[H])=C(OC([H])([H])[H])C([H])=C1* 0.000 description 1
• LAWDSOAXOCOSPV-UHFFFAOYSA-N 3-(3-methylbut-2-enoxy)-4-(3-phenylprop-2-enoyl)xanthen-9-one Chemical compound CC(C)=CCOC1=CC=C(C(C2=CC=CC=C2O2)=O)C2=C1C(=O)C=CC1=CC=CC=C1 LAWDSOAXOCOSPV-UHFFFAOYSA-N 0.000 description 1
• CXKQXJPYPVCTRV-UHFFFAOYSA-N 3-(3-methylbut-2-enoxy)-4-[3-(3,4,5-trimethoxyphenyl)prop-2-enoyl]xanthen-9-one Chemical compound COC1=C(OC)C(OC)=CC(C=CC(=O)C=2C3=C(C(C4=CC=CC=C4O3)=O)C=CC=2OCC=C(C)C)=C1 CXKQXJPYPVCTRV-UHFFFAOYSA-N 0.000 description 1
• AEQVLDDVEGAKDQ-UHFFFAOYSA-N 4-(3-phenylprop-2-enoyl)-3-prop-2-enoxyxanthen-9-one Chemical compound C=CCOC1=CC=C(C(C2=CC=CC=C2O2)=O)C2=C1C(=O)C=CC1=CC=CC=C1 AEQVLDDVEGAKDQ-UHFFFAOYSA-N 0.000 description 1
• NVLXRSGZLQABNZ-UHFFFAOYSA-N 4-[3-(3-methoxyphenyl)prop-2-enoyl]-3-(3-methylbut-2-enoxy)xanthen-9-one Chemical compound COC1=CC=CC(C=CC(=O)C=2C3=C(C(C4=CC=CC=C4O3)=O)C=CC=2OCC=C(C)C)=C1 NVLXRSGZLQABNZ-UHFFFAOYSA-N 0.000 description 1
• 125000004172 4-methoxyphenyl group Chemical group [H]C1=C([H])C(OC([H])([H])[H])=C([H])C([H])=C1* 0.000 description 1
• 208000001132 Osteoporosis Diseases 0.000 description 1
• 125000006615 aromatic heterocyclic group Chemical group 0.000 description 1
• 125000004429 atom Chemical group 0.000 description 1
• 210000000481 breast Anatomy 0.000 description 1
• 238000002648 combination therapy Methods 0.000 description 1
• 229940079593 drug Drugs 0.000 description 1
• 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
• 125000001041 indolyl group Chemical group 0.000 description 1
• 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
• 230000009245 menopause Effects 0.000 description 1
• 238000000034 method Methods 0.000 description 1
• 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
• 125000004433 nitrogen atom Chemical group N* 0.000 description 1
• 210000001672 ovary Anatomy 0.000 description 1
• 229910052760 oxygen Inorganic materials 0.000 description 1
• 125000003854 p-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Cl 0.000 description 1
• 125000001037 p-tolyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)C([H])([H])[H] 0.000 description 1
• 239000000546 pharmaceutical excipient Substances 0.000 description 1
• 230000002265 prevention Effects 0.000 description 1
• 208000016691 refractory malignant neoplasm Diseases 0.000 description 1
• 229910052717 sulfur Inorganic materials 0.000 description 1
• 125000001544 thienyl group Chemical group 0.000 description 1
• 125000001680 trimethoxyphenyl group Chemical group 0.000 description 1
• 210000004291 uterus Anatomy 0.000 description 1